Epitenon-derived progenitor cells in tendon healing and adaptation

表腱衍生的祖细胞在肌腱愈合和适应中的作用

• 批准号: 10852086
• 负责人: Anne E.C. Nichols
• 金额: $ 7.02万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10852086
• 关键词: Ablation; Administrative Supplement; Adrenal Cortex Hormones; Affect; American; Anti-Inflammatory Agents; Area; Award; Behavioral; Biological Markers; Biological Products; Biology; Biomechanics; Cell Differentiation process; Cells; Cellular biology; Clinic; Clinical; Data; Data Set; Dependence; Deposition; Exhibits; Future; Genes; Genetic; Goals; Hand Strength; Histologic; Histology; Immune; Inflammatory; Injury; Intervention; Knock-out; Knowledge; Measurement; Measures; Mediating; Methods; Modeling; Morphology; Mus; Musculoskeletal Diseases; Nociceptors; Non-Steroidal Anti-Inflammatory Agents; Opioid; Outcome Measure; Pain; Pain Research; Pain management; Parents; Pathology; Patients; Persistent pain; Pharmaceutical Preparations; Play; Population; Process; Property; Protease Inhibitor; Public Health; Quality of life; Rheumatism; Rodent; Role; Site; Tendon Injuries; Tendon structure; Testing; Time; Tissues; data reuse; design; efficacy testing; experimental study; functional outcomes; gait examination; healing; improved; innovation; insight; knock-down; mouse model; negative affect; novel; opioid use; pain inhibition; pressure; prevent; progenitor; recruit; response; secondary analysis; single-cell RNA sequencing; skin disorder; stem cells; therapeutic target; treatment effect

Project Summary Pain associated with tendon injuries is an difficult clinical problem that significantly affects the overall quality of life of affected patients. Current treatments for tendon pain are anti-inflammatory drugs (non-steroidal anti- inflammatory drugs (NSAIDS) and corticosteroids) or opioids; however, anti-inflammatory drugs can negatively affect the tendon healing process and long-term opioid use can lead to dependency and contributes to the national opioid public health crisis. Thus, the need for novel, more targeted mechanisms to alleviate pain in tendon injuries is high. The parent award seeks to define the overall role that epitenon cells play in tendon healing using a novel driver (GLASTCreERT) to track and manipulate epitenon cells (GLASTLin) through a combination of genetic lineage tracing, single-cell RNA-sequencing, and depletion/inhibitions studies. This administrative supplement builds on preliminary data gathered during completion of Aim 1 of the parent award wherein we discovered that a GLASTLin epitenon cells are the sole expressors of the peptidase inhibitor 16 (Pi16) gene, a key non-neuronal regulator of persistent pain. This suggests that Pi16 expression by epitenon cells may be a therapeutic target to mitigate the pain associated with tendon injury. Therefore, in parallel with the parent award, the proposed administrative supplement will test the central hypothesis that epitenon-derived cells are primary drivers of the tendon pain response. In supplemental experiments to Aim 2A of the parent award, we will first identify pain-related behavioral metrics that can be used to longitudinally evaluate tendon pain in mouse models. We will then assess how loss of Pi16 via GLASTLin epitenon cell depletion affects the pain response during healing by a combination of histological and pain-related behavioral analyses. Successful completion of these experiments will identify epitenon cell-derived Pi16 as a potential target by which tendon-related pain can be alleviated and establish methods to measure tendon pain in future studies.

项目概要 与肌腱损伤相关的疼痛是一个棘手的临床问题，显着影响患者的整体质量。 受影响患者的生活。目前治疗肌腱疼痛的方法是抗炎药（非甾体类抗炎药） 炎症药物（NSAIDS）和皮质类固醇）或阿片类药物；然而，抗炎药物可能会产生负面影响 影响肌腱愈合过程，长期使用阿片类药物可能导致依赖性并导致 全国阿片类药物公共卫生危机。因此，需要新的、更有针对性的机制来减轻疼痛 肌腱损伤率很高。家长奖旨在明确表腱细胞在肌腱愈合中发挥的总体作用 使用新型驱动程序 (GLASTCreERT) 通过以下组合来跟踪和操纵表腱细胞 (GLASTLin) 遗传谱系追踪、单细胞 RNA 测序和耗尽/抑制研究。本次行政 补充建立在完成家长奖目标 1 期间收集的初步数据的基础上，其中我们 发现 GLASTLin 表腱细胞是肽酶抑制剂 16 (Pi16) 基因的唯一表达者， 持续性疼痛的关键非神经元调节剂。这表明表膜细胞表达 Pi16 可能是 治疗目标是减轻与肌腱损伤相关的疼痛。因此，在发放家长奖的同时， 拟议的行政补充将检验表腱衍生细胞是主要细胞的中心假设 肌腱疼痛反应的驱动因素。在家长奖目标2A的补充实验中，我们首先 确定可用于纵向评估小鼠模型肌腱疼痛的疼痛相关行为指标。 然后，我们将评估 GLASTLin 表腱细胞耗竭导致 Pi16 的损失如何影响治疗过程中的疼痛反应。 通过组织学和疼痛相关行为分析的结合来治愈。顺利完成这些 实验将确定表腱细胞衍生的 Pi16 作为潜在靶标，通过该靶标可以治疗与肌腱相关的疼痛。 缓解并在未来的研究中建立测量肌腱疼痛的方法。